Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC
dc.contributor.author | Doebele, R. C. | |
dc.contributor.author | Perez, L. | |
dc.contributor.author | Trinh, H. | |
dc.contributor.author | Martinec, M. | |
dc.contributor.author | Martina, R. | |
dc.contributor.author | Riehl, T. | |
dc.contributor.author | Krebs, Matthew G | |
dc.contributor.author | Meropol, N. J. | |
dc.contributor.author | Wong, W B | |
dc.contributor.author | Crane, G. | |
dc.date.accessioned | 2021-09-07T13:16:17Z | |
dc.date.available | 2021-09-07T13:16:17Z | |
dc.date.issued | 2021 | en |
dc.identifier.citation | Doebele RC, Perez L, Trinh H, Martinec M, Martina R, Riehl T, et al. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. Journal of Comparative Effectiveness Research. 2021 Aug 24. | en |
dc.identifier.pmid | 34427452 | en |
dc.identifier.doi | 10.2217/cer-2021-0131 | en |
dc.identifier.uri | http://hdl.handle.net/10541/624535 | |
dc.description.abstract | Aim: Generating direct comparative evidence in prospective randomized trials is difficult for rare diseases. Real-world cohorts may supplement control populations. Methods: Entrectinib-treated adults with advanced ROS1 fusion-positive NSCLC (n = 94) from Phase I/II trials (ALKA-372-001 [EudraCT2012-00148-88], STARTRK-1 [NCT02097810], and STARTRK-2 [NCT02568267]) were compared with a real-world crizotinib-treated cohort (n = 65). Primary end point, time-to-treatment discontinuation (TTD); secondary end points, PFS and OS. Results: Median (95% CI) weighted TTD: 12.9 (9.9-17.4) months for entrectinib; 8.8 (6.2-9.9) months for crizotinib (weighted hazard ratio, 0.72 [0.51-1.02]). Median OS with entrectinib was not reached, weighted median OS with crizotinib was 18.5 (15.1-19.9) months. Conclusion: Entrectinib administered in clinical trials may be associated with longer TTD than a real-world crizotinib population. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.2217/cer-2021-0131 | en |
dc.title | Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC | en |
dc.type | Article | en |
dc.contributor.department | Anschutz Medical Campus, University of Colorado, 1665 Aurora Court Anschutz Cancer Pavilion, Aurora, CO 80045, USA | en |
dc.identifier.journal | Journal of Comparative Effectiveness Research | en |
dc.description.note | en] | |
refterms.dateFOA | 2021-09-08T13:19:17Z |